Table 2. Univariate and multivariate analyses of IQGAP3 expression associated with OS in GBMLGG patients in the TCGA-GBMLGG cohort.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | ||
| WHO grade | 634 | ||||
| G2 | 223 | Reference | |||
| G3 | 243 | 2.999 (2.007–4.480) | <0.001 | 1.605 (0.967–2.663) | 0.067 |
| G4 | 168 | 18.615 (12.460–27.812) | <0.001 | 4.565 (1.344–15.508) | 0.015 |
| IDH status | 685 | ||||
| WT | 246 | Reference | |||
| Mut | 439 | 0.117 (0.090–0.152) | <0.001 | 0.455 (0.264–0.785) | 0.005 |
| 1p/19q codeletion | 688 | ||||
| codel | 170 | Reference | |||
| non-codel | 518 | 4.428 (2.885–6.799) | <0.001 | 1.062 (0.553–2.042) | 0.856 |
| Gender | 695 | ||||
| Female | 297 | Reference | |||
| Male | 398 | 1.262 (0.988–1.610) | 0.062 | 1.751 (1.117–2.745) | 0.015 |
| Age | 695 | ||||
| <=60 | 552 | Reference | |||
| >60 | 143 | 4.668 (3.598–6.056) | <0.001 | 4.030 (2.421–6.706) | <0.001 |
| Primary therapy outcome | 461 | ||||
| PD | 112 | Reference | |||
| SD | 147 | 0.440 (0.294–0.658) | <0.001 | 0.342 (0.204–0.571) | <0.001 |
| PR | 64 | 0.170 (0.074–0.391) | <0.001 | 0.188 (0.066–0.532) | 0.002 |
| CR | 138 | 0.133 (0.064–0.278) | <0.001 | 0.160 (0.074–0.347) | <0.001 |
| Histological type | 695 | ||||
| Astrocytoma | 195 | Reference | |||
| Glioblastoma | 168 | 6.791 (4.932–9.352) | <0.001 | ||
| Oligoastrocytoma | 134 | 0.657 (0.419–1.031) | 0.068 | 1.120 (0.645–1.944) | 0.687 |
| Oligodendroglioma | 198 | 0.580 (0.395–0.853) | 0.006 | 0.620 (0.356–1.081) | 0.092 |
| IQGAP3 | 695 | ||||
| Low | 348 | Reference | |||
| High | 347 | 4.372 (3.296–5.801) | <0.001 | 1.418 (0.899–2.236) | 0.033 |